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http://dx.doi.org/10.1016/j.bpj.2012.11.009Amyloid beta (Ab) peptides have long been thought to play
a central role in Alzheimer’s disease (AD). Usually 40 or 42
residues in length, Ab peptides are proteolytic products of
the Ab precursor protein and they aggregate to form the
fibrillar plaques in AD patients’ brains. Besides fibrillar pla-
ques, Ab oligomers are also neurotoxic. The significance
and nature of Ab oligomerization has recently become
a focus of intensive research studies and debates (1,2).
Notably, numerous pathogenic mutations have been identi-
fied in the Ab precursor protein sequence and in the
enzymes involved in Ab processing (3). These mutations
generally lead to early onset of AD or cerebral amyloid an-
giopathy. Understanding how the pathogenic mutations alter
Ab oligomerization/aggregation is essential to our under-
standing of the disease mechanism.
Four of these pathogenic mutations (Italian E22K, Dutch
E22Q, Arctic E22G, and Iowa D23N) cluster in the region of
E22 and D23 in the Ab sequence (distal from proteolytic
cleavage sites) and they have higher neurotoxicity compared
to wild-type (WT) Ab (4). These mutations are thought to
modify the physicochemistry of the peptide. For example,
kinetic studies (4) show that the E22K and E22Q mutations
lead to faster peptide aggregation, whereas the E22G and
D23N mutations result in slightly slower aggregation than
WT Ab42 (although the E22G mutation shows increased
protofibril formation (5)). Recent solid-state NMR studies
also suggest that rather than the in-register b-sheet confor-
mation adopted by WT Ab, the Iowa D23N mutant forms
amyloid fibrils with antiparallel b-sheet structure (6).
To understand how the mutations modify the peptide olig-
omerization/aggregation it is critical to characterize the
starting point of the process, the monomers. Unfortunately,
investigating the early phase of the oligomerization process
experimentally is a challenging task due to the high aggre-
gation propensity of Ab and its intrinsic disorder. Therefore,
a number of computational approaches have been adopted to
investigate the consequences of mutations for the monomerstructure (7–16). However, due to the high computational
demands of explicit-solvent molecular dynamics (MD)
simulations to simulate full-length Ab peptides, most of
these computational studies are either on Ab fragments (to
decrease the system size) using explicit-solvent simulations
(8–12) or on full-length Ab using implicit-solvent simula-
tions (which are less computationally demanding and enable
longer simulation times, but lack explicit water molecules in
the simulations to fully describe water-peptide interactions)
(13–15). In a very recent report, explicit-solvent simulations
were used to study the effects of the E22Q mutation on full-
length Ab; however, rather limited data (<10 ms) were
collected (16). Thus, characterizing full-length Ab mono-
mers remains quite a daunting task even with simulations.
To characterize the effects of mutations on full-length Ab
monomer using explicit-solvent MD simulations, we em-
ployed distributed computing (17) to simulate the WT
Ab42, Ab42-E22K, Ab42-E22Q, Ab42-E22G, and Ab42-
D23N monomers. MD simulations of >200 ms were per-
formed for each system and AMBER ff99sb (18) and the
tip3p water model (19) were used for force field parameters.
Peptide configurations in the MD trajectories were clustered
with the root mean-square deviation metric to identify repre-
sentative conformations (i.e., states) and transitions between
these states were counted. Markov state model analysis was
then performed where the master equations were solved and
the equilibrium population of each state deduced (20).
Details of the MD simulation procedures and Markov state
model analysis can be found in the Supporting Material.
Each of the five Ab monomer systems exhibits great
structural diversity and can only be characterized in an
ensemble fashion (rather than described by a handful of
L48 Biophysical Lettersrepresentative configurations). This is in accord with the
notion that full-length Ab peptides are intrinsically disor-
dered (21,22). Using the Dictionary of Secondary Structure
of Proteins program (23) to assign secondary structure, it is
clear that the five Ab monomer systems are found overall
not well structured, although small b-hairpins and a-helices
are observed. In Fig. 1 we plot the residue-dependent
extended b propensity and a-helix propensity, in the top
and bottom panels, respectively, for each Ab monomer
system. Although we are reasonably confident of the conver-
gence behavior of the a-helix propensity, we note that the
convergence of the extended b-propensity might be more
challenging and demand a much longer sampling time
than the current aggregate simulation time of ~200 ms (24).
We observe in Fig. 1 that all five Ab monomer systems
share a rather similar residue-dependent tendency to form
an extended b-structure, although minor differences are
present. On the other hand, these pathogenic mutations alter
the a-helix propensity quite significantly. The E22K and
E22Q mutations increase the a-helix propensity in the
region of residues 20–23. All four mutations (E22K,
E22Q, E22G, and D23N) decrease the a-helix propensity
in the region of residues 33–36.
Notably, we find that in all five systems only short
stretches of a-helices are formed. That is, when a residue
is involved in a-helix formation, it participates in forming
mostly short helical segments (consisting of only four
helical residues). To provide more insight into the changes
of a-helix propensity due to the mutations, in Fig. S1 we
plot the tendency of forming short a-helices along the
sequence for all five systems. Each data point in Fig. S1
represents the propensity to form an a-helix of four residuesFIGURE 1 Ensemble-averaged %population of b-strand (top)
and a-helix (bottom) propensity for all five monomer systems.
The sequence of the WT Ab42 is given on the x axis.
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structural ensemble adopted by the WT peptide, ~5.5% of
the conformations have a short a-helix of size four,
involving residues 15–18. We see from Fig. S1 that the
E22K and E22Q mutations induce the formation of two
short helices in residues 19–22 and 20–23. The higher
a-helix propensity in this region for the E22K mutant
compared to the WT was previously attributed to the elimi-
nation of the electrostatic repulsion between E22 and D23 in
the WT by the mutation and the longer aliphatic chain of
K22 in the mutant compared to E22 in the WT (9,22).
This is consistent with the observation that the E22Q muta-
tion also induces helix formation in this region (by elimi-
nating the electrostatic repulsion between E22 and D23 in
the WT) but to a lesser extent, possibly due to the shorter
aliphatic chain of Q22 compared to K22.
In the E22G mutant, although the mutation eliminates the
electrostatic repulsion between E22 and D23 in the WT
peptide, glycine is known to be a helix breaker (25), leading
to diminished a-helix propensity in the region around
residue G22 seen in Fig. S1.
In the D23N mutant, although the mutation eliminates the
electrostatic repulsion between E22 and D23 in the WT
peptide, it does not induce (or rather even slightly decreases)
helix formation around residue 23. This may be due to the
short aliphatic chain of N23 but it is possible that the muta-
tion induces some nonlocal effects on the peptide structure,
disfavoring helix formation in this region.
It is worth noting that all four mutations (E22K, E22Q,
E22G, and D23N) virtually eliminate the a-helix propensity
in the region of residues 33–36. This region is rather far away
from themutation sites in sequence but its a-helix propensity
is nonetheless affected. The origin of such a nonlocal effect
is less straightforward to explain and further analysis will
aid untangling this behavior. Nonetheless, the diminished
a-helix propensity in the region of residues 33–36 appears
to be a consistent feature across all four mutants.
The four mutations studied here (E22K, E22Q, E22G, and
D23N) have been thought to modify the physicochemistry of
the peptide and alter the oligomerization/aggregation
process, leading to higher neurotoxicity. In predicting
intrinsic aggregation propensities using peptide sequences,
all four mutants are suggested to be more aggregation prone
(26). On the other hand, kinetic studies show that only the
E22K and E22Q mutants aggregate more quickly, whereas
the E22G and D23N mutations result in slightly slower
aggregation than WT Ab42 (4). Our simulation results
suggest these pathogenicmutations have complicated effects
on themonomer structure—all four mutations decrease helix
propensity in residues 33–36, whereas only the E22K and
E22Q mutations increase helix propensity in residues 20–
23. It is interesting to note thata-helix propensity is generally
thought to anticorrelate with aggregation propensity;
however, recent studies have suggested an important role
of a-helical intermediates in amyloid oligomerization
Biophysical Letters L49(27–29). Our studies suggest that it would be of great value to
investigate how the distinct patterns of a-helix propensity in
these five systems may propagate to give rise to different
oligomerization kinetics or even mechanisms. The patho-
genic mutations studied here have complex effects on the
oligomerization of the peptide. The characterization of the
monomer structural ensembles reported here should aid
understanding of such an important and complicated process.SUPPORTING MATERIAL
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